Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
Market Spotlight: Idiopathic pulmonary fibrosis (IPF)
$1,318.00
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 187,040 incident cases and 714,260 prevalent cases of idiopathic pulmonary fibrosis (IPF) in adults aged 20 years and older worldwide, and forecasts those numbers to increase to 209,960 incident cases and 798,760 prevalent cases by 2028.
- Roche’s Esbriet and Boehringer Ingelheim’s Ofev are the only approved drugs for IPF. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IPF are in Phase I. Therapies in development for IPF focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route.
- High-impact upcoming events in the IPF space comprise topline Phase IIa trial results for PLN-74809, topline Phase IIb trial results for GB0139, topline Phase II trial results for BLD-0409 and C21, as well as topline Phase III trial results for pamrevlumab.
- The overall likelihood of approval of a Phase I respiratory-other asset is 4.9%, and the average probability a drug advances from Phase III is 38.5%. Drugs, on average, take 13.5 years from Phase I to approval, compared to 10.1 years in the overall respiratory space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IPF have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of IPF clinical trials globally. The UK leads the major European markets, while Israel has the top spot in Asia.
- Clinical trial activity in the IPF space is dominated by completed trials. Roche has the highest number of completed clinical trials for IPF, with 20 trials.
- Roche leads
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Pharmacologic treatment
10 Non-pharmacologic treatments
12 EPIDEMIOLOGY
17 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 GLPG1690 for IPF (February 10, 2021)
27 GLPG1205 for IPF (December 1, 2020)
29 KEY UPCOMING EVENTS
30 KEY REGULATORY EVENTS
30 Court Ruling Gives Sandoz Canada First Generic Pirfenidone
31 PROBABILITY OF SUCCESS
32 LICENSING AND ASSET ACQUISITION DEALS
32 Lassen, Cedars-Sinai Investigate Role Of IL-11 In Lung Fibrosis
32 Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
32 Bridge, LegoChem Team To Speed Development Of Autotaxin Inhibitor
32 Galapagos Teams With Poland’s OncoArendi On IPF Candidate
33 Boehringer, Bridge IPF Deal Collapses On Toxicity Concerns
33 Reborn Redx Inks Global Licensing Deal With AstraZeneca
34 REVENUE OPPORTUNITY
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
38 Recent events
39 BIBLIOGRAPHY
41 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of IPF, 2019–28
16 Figure 2: Trends in prevalent cases of IPF, 2019–28
19 Figure 3: Overview of pipeline drugs for IPF in the US
19 Figure 4: Pipeline drugs for IPF, by company
20 Figure 5: Pipeline drugs for IPF, by drug type
20 Figure 6: Pipeline drugs for IPF, by classification
28 Figure 7: GLPG1205 for IPF (December 1, 2020): Phase II – PINTA
29 Figure 8: Key upcoming events in IPF
31 Figure 9: Probability of success in the respiratory-other pipeline
35 Figure 10: Clinical trials in IPF
35 Figure 11: Top 10 drugs for clinical trials in IPF
36 Figure 12: Top 10 companies for clinical trials in IPF
36 Figure 13: Trial locations in IPF
37 Figure 14: IPF trials status
38 Figure 15: IPF trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of IPF, 2019–28
15 Table 2: Prevalent cases of IPF, 2019–28
18 Table 3: Marketed drugs for IPF
21 Table 4: Pipeline drugs for IPF in the US
26 Table 5: GLPG1690 for IPF (February 10, 2021)
27 Table 6: GLPG1205 for IPF (December 1, 2020)
34 Table 7: Historical global sales, by drug ($m), 2016–20
34 Table 8: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Atrial Fibrillation 
Sign up to the